HIV Prophylaxis in Sexual Assault Questions & Answers

1. FDA. US FDA. Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate - Potential Risk of Neural Tube Birth Defects. May 18, 2018. Available at https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm608168.htm.

2. CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR. 2001;. 50 (No. RR-11).:

3. Roland ME, Neilands TB, Krone MR, Coates TJ, Franses K, Chesney MA, et al. A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV. Clin Infect Dis. 2011 Jul 1. 53(1):76-83. [Medline]. [Full Text].

4. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol. 2000 Jul. 74(13):6087-95. [Medline].

5. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998 May. 72(5):4265-73. [Medline]. [Full Text].

6. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000 Oct. 74(20):9771-5. [Medline]. [Full Text].

7. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D. Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997 Nov 20. 337(21):1485-90. [Medline].

8. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999 Sep 4. 354(9181):795-802. [Medline].

9. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3. 331(18):1173-80. [Medline].

10. Gray GE, Urban M, Chersich MF, Bolton C, van Niekerk R, Violari A, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005 Aug 12. 19(12):1289-97. [Medline].

11. Taha TE, Kumwenda NI, Gibbons A, Broadhead RL, Fiscus S, Lema V. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet. 2003 Oct 11. 362(9391):1171-7. [Medline].

12. [Guideline] Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. Dec 17, 2010. 59(RR-12):1-116.

13. Harrison LH, Do Lago RF, Moreira RI. , Schechter M. Demand for post-sexual-exposure chemoprophylaxis for the prevention of HIV infection in Brazil [abstract 492]. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California: , January 30–February 2, 2000.

14. Drezett J. Postexposure prophylaxis in raped women. IV International Conference on HIV infection in women and children. Rio de Janeiro.: Livro de Resumos. Universidade, Federal do Rio De Janeiroe Institute of Virology of Maryland; 2002.

15. Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney M, Chambers D, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis. 2001 Mar 1. 183(5):707-14. [Medline].

16. Fournier S, Maillard A, Molina JM. Failure of postexposure prophylaxis after sexual exposure to HIV. AIDS. 2001 Feb 16. 15(3):430. [Medline].

17. Beltrami EM, Luo C-C, De La Torre N, Cardo DM. Transmission of a drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol. 2002. 23:345–8.

18. Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immun Defic Syndr. 2004. 35:519 – 525.

19. Grohskopf LA, Smith DK, Kunches LM, et al. Surveillance of postexposure prophylaxis for nonoccupational HIV exposures through the U.S. National Registry. AIDS 2002 XIV International AIDS Conference. Barcelona, Spain: 11 July 2002.

20. Grulich A, Zheng W, Kippax S, Smith DE. Highly targeted use of nonoccupa-tional postexposure prophylaxis (NPEP) in Australia. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France: 13– 16 July 2003.

21. [Guideline] Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. [Full Text].

22. Rodger AJ, Cambiano V, Bruun T, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. Jul 2016. 316(2):171-81. [Medline]. [Full Text].

23. [Guideline] Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidem. Sept 2013. 34(9):874-92. [Medline]. [Full Text].

24. Wilson DP1, Law MG, Grulich AE et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet. July 2008. 372(9635):314-20. [Medline]. [Full Text].

25. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. FDA News Release. October 5, 2018. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm.

26. Ford N, Mayer KH, World Health Organization Postexposure Prophylaxis Guideline Development Group. World Health Organization Guidelines on Postexposure Prophylaxis for HIV: Recommendations for a Public Health Approach. Clin Infect Dis. 2015 Jun 1. 60 Suppl 3:S161-4. [Medline].

27. Avegno J, Mills TJ, Mills LD. Sexual assault victims in the emergency department: analysis by demographic and event characteristics. J Emerg Med. 2009 Oct. 37(3):328-34. [Medline].

28. Albert J, Wahlberg J, Leitner T, Escanilla D, Uhlén M. Analysis of a rape case by direct sequencing of the human immunodeficiency virus type 1 pol and gag genes. J Virol. 1994 Sep. 68(9):5918-24. [Medline]. [Full Text].

29. Claydon E, Murphy S, Osborne EM, Kitchen V, Smith JR, Harris JR. Rape and HIV. Int J STD AIDS. 1991 May-Jun. 2(3):200-1. [Medline].

30. Murphy S, Kitchen V, Harris JR, Forster SM. Rape and subsequent seroconversion to HIV. BMJ. 1989 Sep 16. 299(6701):718. [Medline]. [Full Text].

31. Gostin LO, Lazzarini Z, Alexander D, Brandt AM, Mayer KH, Silverman DC. HIV testing, counseling, and prophylaxis after sexual assault. JAMA. 1994 May 11. 271(18):1436-44. [Medline].

32. Linden JA. Clinical practice. Care of the adult patient after sexual assault. N Engl J Med. 2011 Sep 1. 365(9):834-41. [Medline].

33. Jenny C , Hooton TM, Bowers A, et al. Sexually transmitted diseases in victims of rape. NEngl J Med. 1990. 322:713-16.

34. Royce RA, Seña A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997 Apr 10. 336(15):1072-8. [Medline].

35. Sperling RS, Shapiro DE, Coombs RW, et al. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996. 335(22):1621–9.

36. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009 Feb. 9(2):118-29. [Medline].

37. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000 Mar 30. 342(13):921-9. [Medline].

38. Tobsian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009. 360:1298–30916.

39. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA. 2008 Oct 8. 300(14):1674-84. [Medline].

40. UNAIDS, WHO. New data on male circumcision and HIV prevention: policy and programme implications: WHO/UNAIDS technical consultation male circumcision and HIV prevention—research implications for policy and programming. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2007.

41. Smith DK, Taylor A, Kilmarx PH, Sullivan P, Warner L, Kamb M. Male circumcision in the United States for the prevention of HIV infection and other adverse health outcomes: report from a CDC consultation. Public Health Rep. 2010 Jan-Feb. 125 Suppl 1:72-82. [Medline].

42. Centers for Disease Control and Prevention, Smith DK, Grohskopf, LA, et al. Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States. Recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. Jan 21, 2005;. 54(RR-2):1-28. [Full Text].

43. [Guideline] New York State Department of Health. HIV prophylaxis following nonoccupational exposure including sexual assault. Jan 2008. [Full Text].

44. California Task Force on Nonoccupational PEP and the California Department of Health Services. Offering HIV postexposure prophylaxis (PEP) following nonoccupational exposures. Recommendations for health care providers in the state of California. Sacramento, CA: California Department of Health Services, Office of AIDS,; 2004.

45. Nonoccupational HIV PEP Task Force. Nonoccupational human immunodeficiency virus postexposure prophylaxis guidelines for Rhode Island healthcare practitioners. Providence, RI: Brown University AIDS Program; 2002.

46. Jones JS, Rossman L, Diegel R, Van Order P, Wynn BN. Sexual assault in postmenopausal women: epidemiology and patterns of genital injury. Am J Emerg Med. 2009 Oct. 27(8):922-9. [Medline].

47. WHO. Postexposure prophylaxis to prevent HIV infection : joint WHO/ILO guidelines on postexposure prophylaxis (PEP) to prevent HIV infection. 200726).

48. Wiebe ER, Comay SE, McGregor M, Ducceschi S. Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service. CMAJ. 2000 Mar 7. 162(5):641-5. [Medline]. [Full Text].

49. Ford N, Irvine C, Shubber Z, Baggaley R, Beanland R, Vitoria M, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS. 2014 Nov 28. 28 (18):2721-7. [Medline].

50. Garcia MT, Figueiredo RM, Moretti ML, Resende MR, Bedoni AJ, Papaiordanou PM. Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Transm Dis. 2005 Apr. 32(4):214-9. [Medline].

51. Meel BL. HIV/AIDS post-exposure prophylaxis (PEP) for victims of sexual assault in South Africa. Med Sci Law. 2005 Jul. 45(3):219-24. [Medline].

52. National Center for Victims of Crime. HIV/AIDS and the Sexual Assault Survivor, 2008. HIV/AIDS & Victim Services, 2001. HIV/AIDS Legislation, 1999. Available at http://www.ncvc.org. Accessed: 5/14/12.

53. National Victim Center, Crime Victims Research and Treatment Center. National Committee for Prevention of Child Abuse. National Women's Study. Rape in America: A Report to the Nation. Arlington, Va: National Victim Center, Crime Victims Research and Treatment Center, Dept of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.; April 23, 1992.

54. U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at http://www.aidsinfo.nih.gov/guidelines/. Accessed: 7/7/2012.

55. C. Bradley Hare. Clinical Overview of HIV. HIV InSite Knowledge Base Chapter. Jan 2006. Content reviewed Dec 08, 2009. Available at http://hivinsite.ucsf.edu. Accessed: 7/19/2012.

56. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconver-sion. Ann Intern Med. 1995. 122:573-9.

57. Wei X, Ghosh SO, Taylor ME. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995. 373:117-22.

58. Apoola A, Ahmad S, Radcliffe K. Primary HIV infection. Int J STD AIDS. Feb 2002. 13:71-78.

59. Krause KH, Lewis-O'Connor A, Berger A, Votto T, Yawetz S, Pallin DJ, et al. Current practice of HIV postexposure prophylaxis treatment for sexual assault patients in an emergency department. Womens Health Issues. 2014 Jul-Aug. 24 (4):e407-12. [Medline].

60. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis,. 2004. 39:395–401.

61. Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med,. October 2009. 361(18):1768–75.

62. Wang SA, Panlilio AL, Doi PA, White AD, Stek M Jr, Saah A. HIV PEP Registry Group. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol. 2000. 21:780–5.

63. Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf. 2001. 24(8):587-97. [Medline].

64. Quirino T, Niero F, Ricci E, Pusterla L, Carradori S, Gabbuti A, et al. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther. 2000 Sep. 5(3):195-7. [Medline].

65. CDC. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures–worldwide, 1997–2000. MMWR. 2001. 49:1153–6.

66. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999 Dec 16. 341(25):1865-73. [Medline].

67. AIDSinfo Drug Database. [Full Text].

68. [Guideline] HIV Prophylaxis Following Non-Occupational Exposure. October 2014. [Full Text].

69. Sexually Transmitted Diseases Treatment Guidelines, 2015. Center for Disease Control and Prevention Morbidity and Mortality Weekly Report. June 5, 2015. 64:[Full Text].

Derek T Larson, DO Chief, Infectious Disease Service, Fort Belvoir Community Hopsital

Derek T Larson, DO is a member of the following medical societies: Armed Forces Infectious Diseases Society, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Ryan C Maves, MD, FACP, FCCP, FIDSA Attending Physician in Infectious Diseases and Critical Care Medicine, Naval Medical Center San Diego; Associate Professor of Medicine, Uniformed Services University of the Health Sciences

Ryan C Maves, MD, FACP, FCCP, FIDSA is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, Armed Forces Infectious Diseases Society, HIV Medicine Association, Infectious Diseases Society of America, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Hina Z Ghory, MD Associate Physician, Department of Emergency Medicine, Robert Wood Johnson University Hospital at Hamilton

Hina Z Ghory, MD is a member of the following medical societies: American College of Emergency Physicians, Phi Beta Kappa

Disclosure: Nothing to disclose.

Joyce S Kuo, MD Resident Physician, Department of Emergency Medicine, New York-Presbyterian Hospital

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article